|Bid||0.00 x 800|
|Ask||17.00 x 800|
|Day's Range||12.42 - 13.84|
|52 Week Range||3.61 - 16.50|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.15|
If you own shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) then it's worth thinking about how it contributes to the...
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
The Zacks Analyst Blog Highlights: Fulgent Genetics, Teekay Tankers, Ultra Clean, Boot Barn and Sonic Automotive
How far off is Fulgent Genetics, Inc. (NASDAQ:FLGT) from its intrinsic value? Using the most recent financial data...
A live webcast of the question and answer session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times.
Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals
The Company has also granted the underwriters a 30-day option to purchase up to 348,750 additional shares of common stock. The Company currently intends to use the net proceeds from this offering for working capital and general corporate purposes. The shares are being offered by Fulgent Genetics by means of a prospectus supplement to the prospectus forming a part of the Company’s effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2019 and other related documents.
In connection with this offering, Fulgent Genetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Fulgent Genetics. The Company currently intends to use the net proceeds from this offering for working capital and general corporate purposes.
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Third Quarter 2019 Results: Record billable tests of 20,697, growing 272% year over yearRecord revenue of $10.3 million, growing 84% year over yearGross Margin improves 8.9.
Fulgent Genetics, Inc. (FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2019 financial results after the market closes on Monday November 4, 2019. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care.
Ming Hsieh has been the CEO of Fulgent Genetics, Inc. (NASDAQ:FLGT) since 2016. This report will, first, examine the...
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
Fulgent Genetics (FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced the launch of Picture Genetics, a new line of at-home genetic testing offerings for the everyday consumer. Picture Genetics will offer three separate consumer-initiated screening tests, which will enable individuals to access Fulgent’s advanced genetic testing and analytics capabilities from the ease and comfort of home at an affordable price point.